Sub menu

 

 

Samsung Bioepis AU Pty Ltd

Regulatory activities for this sponsor.

Type

Date

Filters applied:Clear all
7 result(s) found, displaying 1 to 7

  • Ospomyv, Xborso

    Australian public assessment report (AusPar)
    Ospomyv, Xborso (denosumab) have been approved for the prevention and treatment of multiple bone-related pathologies.

  • Opuviz

    Australian public assessment report (AusPar)
    Opuviz, a bioisimilar to Eylea, has been approved for multiple eye-related conditions.

  • AusPAR: Onbevzi

    Australian public assessment report (AusPar)
    Onbevzi (bevacizumab) is a biosimilar of Avastin. Onbevzi has been approved to treat a range of cancers either as a monotherapy or in combination with other anti-cancer medicines

  • AusPAR: Byooviz

    Australian public assessment report (AusPar)
    Byooviz (ranibizumab) for the treatment of neovascular age-related macular degeneration etc.

  • AusPAR: Adalimumab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Adalimumab

  • AusPAR: Infliximab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for infliximab

  • AusPAR: Etanercept (rch)

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Brenzys